In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

The company submission assumes that red blood cell transfusions are typically given every 6 weeks ... Then, the CRISPR associated protein 9 is used to edit the BCL11A gene before the cells are frozen.

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of ...

Maxcyte's technology helped Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) to develop the world's first FDA-approved gene-editing treatment for sickle cell ...

Can we predict that natural selection will weed out genetic disease over time? Sickle-cell trait haplotype distribution shows the genetic advantages of this mutation. In the deoxygenated ...